NEIM-02 DEVELOPMENT OF A DEEP LEARNING MODEL FOR DISCRIMINATING TRUE PROGRESSION FROM PSEUDOPROGRESSION IN GLIOBLASTOMA PATIENTS

INTRODUCTION: Glioblastomas (GBMs) are highly aggressive tumors. Despite multimodal treatment, its median overall survival ranges between 16 and 20 months. The standard treatment regimen consists of surgical resection followed by concurrent chemoradiotherapy and adjuvant temozolomide. Despite temozo...

Descripción completa

Detalles Bibliográficos
Autores principales: Moassefi, Mana, Faghani, Shahriar, Conte, Gian Marco, Rouzrokh, Pouria, Kowalchuk, Roman O, Trifiletti, Daniel, Erickson, BradleyJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354212/
http://dx.doi.org/10.1093/noajnl/vdac078.069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354212/
http://dx.doi.org/10.1093/noajnl/vdac078.069

Ejemplares similares